{"id":"https://openalex.org/W2948684351","doi":"https://doi.org/10.2337/db19-1139-p","title":"1139-P: Influence of Screening HbA1c Levels on Glucose Control Achieved when Switching to iGlarLixi in T2D Inadequately Controlled on GLP-1RA and OAD(s)","display_name":"1139-P: Influence of Screening HbA1c Levels on Glucose Control Achieved when Switching to iGlarLixi in T2D Inadequately Controlled on GLP-1RA and OAD(s)","publication_year":2019,"publication_date":"2019-06-01","ids":{"openalex":"https://openalex.org/W2948684351","doi":"https://doi.org/10.2337/db19-1139-p","mag":"2948684351"},"language":"en","primary_location":{"id":"doi:10.2337/db19-1139-p","doi":"https://doi.org/10.2337/db19-1139-p","is_oa":false,"landing_page_url":"https://doi.org/10.2337/db19-1139-p","pdf_url":null,"source":{"id":"https://openalex.org/S129060628","display_name":"Diabetes","issn_l":"0012-1797","issn":["0012-1797","1939-327X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320274","host_organization_name":"American Diabetes Association","host_organization_lineage":["https://openalex.org/P4310320274"],"host_organization_lineage_names":["American Diabetes Association"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Diabetes","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5019711625","display_name":"Stefano Del Prato","orcid":"https://orcid.org/0000-0002-5388-0270","observed_orcids":["https://orcid.org/0000-0002-5388-0270","https://orcid.org/0000-0001-5905-0211"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"STEFANO DEL PRATO","raw_affiliation_strings":["Pisa, Italy, New Orleans, LA, San Diego, CA, Boston, MA, Haifa, Israel, Frankfurt, Germany, Paris, France, Beijing, China, Dallas, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pisa, Italy, New Orleans, LA, San Diego, CA, Boston, MA, Haifa, Israel, Frankfurt, Germany, Paris, France, Beijing, China, Dallas, TX","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5070289715","display_name":"Lawrence Blonde","orcid":"https://orcid.org/0000-0003-0492-6698","observed_orcids":["https://orcid.org/0000-0003-0492-6698"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"LAWRENCE BLONDE","raw_affiliation_strings":["Pisa, Italy, New Orleans, LA, San Diego, CA, Boston, MA, Haifa, Israel, Frankfurt, Germany, Paris, France, Beijing, China, Dallas, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pisa, Italy, New Orleans, LA, San Diego, CA, Boston, MA, Haifa, Israel, Frankfurt, Germany, Paris, France, Beijing, China, Dallas, TX","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5045462483","display_name":"Robert R. Henry","orcid":"https://orcid.org/0000-0002-4821-0117","observed_orcids":["https://orcid.org/0000-0002-4821-0117"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"ROBERT R. HENRY","raw_affiliation_strings":["Pisa, Italy, New Orleans, LA, San Diego, CA, Boston, MA, Haifa, Israel, Frankfurt, Germany, Paris, France, Beijing, China, Dallas, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pisa, Italy, New Orleans, LA, San Diego, CA, Boston, MA, Haifa, Israel, Frankfurt, Germany, Paris, France, Beijing, China, Dallas, TX","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5005405894","display_name":"Vanita R. Aroda","orcid":"https://orcid.org/0000-0002-7706-4585","observed_orcids":["https://orcid.org/0000-0002-7706-4585"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"VANITA R. ARODA","raw_affiliation_strings":["Pisa, Italy, New Orleans, LA, San Diego, CA, Boston, MA, Haifa, Israel, Frankfurt, Germany, Paris, France, Beijing, China, Dallas, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pisa, Italy, New Orleans, LA, San Diego, CA, Boston, MA, Haifa, Israel, Frankfurt, Germany, Paris, France, Beijing, China, Dallas, TX","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5042407874","display_name":"Naim Shehadeh","orcid":"https://orcid.org/0000-0003-3158-6254","observed_orcids":["https://orcid.org/0000-0003-3158-6254","https://orcid.org/0009-0000-5074-8242"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"NAIM SHEHADEH","raw_affiliation_strings":["Pisa, Italy, New Orleans, LA, San Diego, CA, Boston, MA, Haifa, Israel, Frankfurt, Germany, Paris, France, Beijing, China, Dallas, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pisa, Italy, New Orleans, LA, San Diego, CA, Boston, MA, Haifa, Israel, Frankfurt, Germany, Paris, France, Beijing, China, Dallas, TX","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5039117287","display_name":"Elisabeth Niemoeller","orcid":"https://orcid.org/0009-0004-4900-6259","observed_orcids":["https://orcid.org/0009-0004-4900-6259"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"ELISABETH NIEMOELLER","raw_affiliation_strings":["Pisa, Italy, New Orleans, LA, San Diego, CA, Boston, MA, Haifa, Israel, Frankfurt, Germany, Paris, France, Beijing, China, Dallas, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pisa, Italy, New Orleans, LA, San Diego, CA, Boston, MA, Haifa, Israel, Frankfurt, Germany, Paris, France, Beijing, China, Dallas, TX","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5040943514","display_name":"Elisabeth Souhami","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"ELISABETH SOUHAMI","raw_affiliation_strings":["Pisa, Italy, New Orleans, LA, San Diego, CA, Boston, MA, Haifa, Israel, Frankfurt, Germany, Paris, France, Beijing, China, Dallas, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pisa, Italy, New Orleans, LA, San Diego, CA, Boston, MA, Haifa, Israel, Frankfurt, Germany, Paris, France, Beijing, China, Dallas, TX","institution_ids":[]}]},{"author_position":"middle","author":{"id":null,"display_name":"JUNLONG WU","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"JUNLONG WU","raw_affiliation_strings":["Pisa, Italy, New Orleans, LA, San Diego, CA, Boston, MA, Haifa, Israel, Frankfurt, Germany, Paris, France, Beijing, China, Dallas, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pisa, Italy, New Orleans, LA, San Diego, CA, Boston, MA, Haifa, Israel, Frankfurt, Germany, Paris, France, Beijing, China, Dallas, TX","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5102977853","display_name":"Xiangling Wang","orcid":"https://orcid.org/0000-0001-5228-7603","observed_orcids":["https://orcid.org/0000-0001-5228-7603"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"XIANGLING WANG","raw_affiliation_strings":["Pisa, Italy, New Orleans, LA, San Diego, CA, Boston, MA, Haifa, Israel, Frankfurt, Germany, Paris, France, Beijing, China, Dallas, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pisa, Italy, New Orleans, LA, San Diego, CA, Boston, MA, Haifa, Israel, Frankfurt, Germany, Paris, France, Beijing, China, Dallas, TX","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5029786470","display_name":"Chen Feng Ji","orcid":"https://orcid.org/0000-0002-9016-6623","observed_orcids":["https://orcid.org/0000-0002-9016-6623"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"CHEN JI","raw_affiliation_strings":["Pisa, Italy, New Orleans, LA, San Diego, CA, Boston, MA, Haifa, Israel, Frankfurt, Germany, Paris, France, Beijing, China, Dallas, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pisa, Italy, New Orleans, LA, San Diego, CA, Boston, MA, Haifa, Israel, Frankfurt, Germany, Paris, France, Beijing, China, Dallas, TX","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5045489578","display_name":"Julio Rosenstock","orcid":"https://orcid.org/0000-0001-8324-3275","observed_orcids":["https://orcid.org/0000-0001-8324-3275"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"JULIO ROSENSTOCK","raw_affiliation_strings":["Pisa, Italy, New Orleans, LA, San Diego, CA, Boston, MA, Haifa, Israel, Frankfurt, Germany, Paris, France, Beijing, China, Dallas, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pisa, Italy, New Orleans, LA, San Diego, CA, Boston, MA, Haifa, Israel, Frankfurt, Germany, Paris, France, Beijing, China, Dallas, TX","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.1332,"has_fulltext":false,"cited_by_count":1,"citation_normalized_percentile":{"value":0.54284293,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":93},"biblio":{"volume":"68","issue":"Supplement_1","first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":0.98580002784729,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":0.98580002784729,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10560","display_name":"Diabetes Management and Research","score":0.011599999852478504,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10027","display_name":"Diabetes, Cardiovascular Risks, and Lipoproteins","score":0.0003000000142492354,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/iglarlixi","display_name":"iGlarLixi","score":0.972000002861023},{"id":"https://openalex.org/keywords/type-2-diabetes","display_name":"type 2 diabetes","score":0.9290000200271606},{"id":"https://openalex.org/keywords/inadequate-glycemic-control","display_name":"inadequate glycemic control","score":0.7549999952316284},{"id":"https://openalex.org/keywords/glp-1-receptor-agonists","display_name":"GLP-1 receptor agonists","score":0.9330000281333923},{"id":"https://openalex.org/keywords/glycemic-control","display_name":"glycemic control","score":0.8289999961853027},{"id":"https://openalex.org/keywords/symptomatic-hypoglycemia","display_name":"symptomatic hypoglycemia","score":0.9900000095367432},{"id":"https://openalex.org/keywords/insulin-therapy-switching","display_name":"insulin therapy switching","score":0.35100001096725464},{"id":"https://openalex.org/keywords/metformin","display_name":"metformin","score":0.5669999718666077},{"id":"https://openalex.org/keywords/pioglitazone","display_name":"pioglitazone","score":0.9559999704360962},{"id":"https://openalex.org/keywords/sglt2-inhibitors","display_name":"SGLT2 inhibitors","score":0.996999979019165},{"id":"https://openalex.org/keywords/oral-antidiabetic-drugs","display_name":"oral antidiabetic drugs","score":0.7540000081062317}],"concepts":[{"id":"https://openalex.org/C2776442814","wikidata":"https://www.wikidata.org/wiki/Q6659956","display_name":"Lixisenatide","level":5,"score":0.8791460990905762},{"id":"https://openalex.org/C2780533449","wikidata":"https://www.wikidata.org/wiki/Q417762","display_name":"Exenatide","level":4,"score":0.7532510161399841},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.722034215927124},{"id":"https://openalex.org/C2781308992","wikidata":"https://www.wikidata.org/wiki/Q2526479","display_name":"Liraglutide","level":4,"score":0.7159954309463501},{"id":"https://openalex.org/C2779829264","wikidata":"https://www.wikidata.org/wiki/Q21011228","display_name":"Dulaglutide","level":5,"score":0.6878122687339783},{"id":"https://openalex.org/C2777180221","wikidata":"https://www.wikidata.org/wiki/Q3025883","display_name":"Type 2 diabetes","level":3,"score":0.634587287902832},{"id":"https://openalex.org/C2779920387","wikidata":"https://www.wikidata.org/wiki/Q417317","display_name":"Insulin glargine","level":4,"score":0.5556029081344604},{"id":"https://openalex.org/C2780473172","wikidata":"https://www.wikidata.org/wiki/Q5572518","display_name":"Glycemic","level":3,"score":0.49768832325935364},{"id":"https://openalex.org/C3018260909","wikidata":"https://www.wikidata.org/wiki/Q1322871","display_name":"Exploratory analysis","level":2,"score":0.48401376605033875},{"id":"https://openalex.org/C2780323712","wikidata":"https://www.wikidata.org/wiki/Q19484","display_name":"Metformin","level":3,"score":0.4751315414905548},{"id":"https://openalex.org/C2780668416","wikidata":"https://www.wikidata.org/wiki/Q202758","display_name":"Hypoglycemia","level":3,"score":0.4339219927787781},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.4323250353336334},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.3135199546813965},{"id":"https://openalex.org/C2779306644","wikidata":"https://www.wikidata.org/wiki/Q2002370","display_name":"Insulin","level":2,"score":0.23604145646095276},{"id":"https://openalex.org/C555293320","wikidata":"https://www.wikidata.org/wiki/Q12206","display_name":"Diabetes mellitus","level":2,"score":0.23005560040473938},{"id":"https://openalex.org/C41008148","wikidata":"https://www.wikidata.org/wiki/Q21198","display_name":"Computer science","level":0,"score":0.0},{"id":"https://openalex.org/C2522767166","wikidata":"https://www.wikidata.org/wiki/Q2374463","display_name":"Data science","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.2337/db19-1139-p","doi":"https://doi.org/10.2337/db19-1139-p","is_oa":false,"landing_page_url":"https://doi.org/10.2337/db19-1139-p","pdf_url":null,"source":{"id":"https://openalex.org/S129060628","display_name":"Diabetes","issn_l":"0012-1797","issn":["0012-1797","1939-327X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320274","host_organization_name":"American Diabetes Association","host_organization_lineage":["https://openalex.org/P4310320274"],"host_organization_lineage_names":["American Diabetes Association"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Diabetes","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2948035380","https://openalex.org/W3128443930","https://openalex.org/W2973598479","https://openalex.org/W4281860551","https://openalex.org/W2946709917","https://openalex.org/W2948580033","https://openalex.org/W3203217829","https://openalex.org/W2770254209","https://openalex.org/W2949006541","https://openalex.org/W3168909431"],"abstract_inverted_index":{"Effects":[0],"of":[1,8,54,200],"switching":[2,33],"to":[3,34],"a":[4,27,50,55,197],"titratable":[5],"fixed-ratio":[6],"combination":[7],"insulin":[9],"glargine":[10],"plus":[11],"lixisenatide":[12],"(iGlarLixi)":[13],"in":[14,41,112,158,180],"patients":[15],"(pts)":[16],"with":[17,43,70,95,171,174,182],"T2D":[18,44,183],"on":[19,186],"GLP-1":[20,38,56,85,147,156,175,187],"RAs":[21,157,176],"have":[22],"been":[23],"unknown.":[24],"LixiLan-G":[25],"(NCT02787551),":[26],"randomized,":[28],"open-label,":[29],"26-week":[30,113],"trial,":[31],"compared":[32],"iGlarLixi":[35,133,153,172,191],"vs.":[36,140],"continued":[37],"RA":[39,57,86,188],"use":[40],"pts":[42,181],"and":[45,88,108,124,137,143,189,217,329,374,425,512],"HbA1c":[46,103,120,130,201],"7-9%":[47],"despite":[48],"receiving":[49],"maximum":[51],"tolerated":[52],"dose":[53],"(liraglutide":[58],"QD,":[59],"exenatide":[60,62],"BID,":[61],"extended-release":[63],"QW,":[64,66],"albiglutide":[65],"or":[67,90],"dulaglutide":[68],"QW)":[69],"metformin":[71],"\u00b1":[72,74],"pioglitazone":[73,89],"SGLT2i.":[75],"Treatment":[76],"effects":[77],"seen":[78],"across":[79,196],"baseline":[80],"factors,":[81],"such":[82],"as":[83],"BMI,":[84],"type,":[87],"SGLT2i":[91],"use,":[92],"were":[93,134,150,166],"consistent":[94],"the":[96],"primary":[97],"analysis.":[98],"This":[99],"exploratory":[100],"analysis":[101],"examined":[102],"change":[104],"at":[105],"week":[106,127],"26":[107],"documented":[109],"symptomatic":[110],"hypoglycemia":[111,164],"completers":[114],"(modified":[115],"ITT)":[116],"by":[117],"screening":[118],"subgroup":[119],"levels":[121,131],"(\u22647.5%,":[122],">7.5-\u22648%,":[123],">8%).":[125],"At":[126],"26,":[128],"mean":[129],"for":[132,146,152,155],"6.6%,":[135,136],"6.9%,":[138],"respectively,":[139,145],"7.2%,":[141],"7.4%,":[142],"7.5%,":[144],"RAs.":[148],"Reductions":[149],"greater":[151],"than":[154,173],"all":[159],"subgroups":[160],"(p<0.0001;":[161],"Figure).":[162],"Symptomatic":[163],"rates":[165],"low":[167],"overall":[168],"but":[169],"higher":[170],"(Figure).":[177],"In":[178],"conclusion,":[179],"inadequately":[184],"controlled":[185],"OAD(s),":[190],"demonstrated":[192],"additional":[193],"glycemic":[194],"benefit":[195],"broad":[198],"range":[199],"levels.":[202],"Disclosure":[203],"S.":[204],"Del":[205],"Prato:":[206],"Advisory":[207,311,408],"Panel;":[208,312,409],"Self;":[209,240,244,252,264,282,300,313,318,326,333,341,345,369,390,410,422,435,438,443,451,456,464,473,505],"AstraZeneca,":[210,245,347,371,391,411,474],"Boehringer":[211,246,253,348,412,506],"Ingelheim":[212,247,254,349,413,507],"Pharmaceuticals,":[213,248,255,269,284,287,302,320,323,350,359,414,483,486,497,518],"Inc.,":[214,256,267,270,274,277,285,288,292,295,303,306,321,351,354,360,364,378,395,402,415,418,479,484,487,495,516,519,522],"Eli":[215,327,423,510],"Lilly":[216,328,424,511],"Company,":[218,375,426,477,513],"GlaxoSmithKline":[219,480],"plc.,":[220,481],"Merck":[221,271,289,361,384,427,492],"Sharp":[222,428],"&":[223,272,290,356,362,385,398,429,446,459,467,493],"Dohme":[224,430],"Corp.,":[225],"Novartis":[226],"Pharmaceuticals":[227],"Corporation,":[228],"Novo":[229,275,293,304,376,400,416,520],"Nordisk":[230,276,294,305,377,401,417,521],"A/S,":[231],"Sanofi,":[232,379,403],"Servier,":[233],"Takeda":[234,257],"Pharmaceutical":[235,258],"Company":[236,259],"Limited.":[237,260],"Board":[238],"Member;":[239],"AstraZeneca.":[241],"Research":[242,280,331,388,397,445,458,466,471],"Support;":[243,281,332,389,472],"Inc.":[249,316,324,338,381,387,405,502],"Speaker's":[250,298,339,420],"Bureau;":[251,299,340,421],"L.":[261],"Blonde:":[262],"Consultant;":[263,317,368],"Gilead":[265],"Sciences,":[266],"Janssen":[268,283,301,396,517],"Co.,":[273,291,363,386,490,494,499],"Sanofi":[278,296,307,444,457,465,525],"US.":[279,297,308],"Lexicon":[286,358,482],"R.R.":[309],"Henry:":[310],"Elcelyx":[314],"Therapeutics,":[315,353,515],"Diasome":[319],"Ionis":[322],"Employee;":[325,382,434,442,450,455,463],"Company.":[330],"AstaReal,":[334],"Hitachi,":[335],"Ltd.,":[336,491,500],"Viacyte,":[337],"Servier.":[342],"Other":[343,503],"Relationship;":[344,504],"Abbott,":[346],"Intarcia":[352,514],"Johnson":[355],"Johnson,":[357],"Sanofi-Aventis.":[365,419],"V.R.":[366],"Aroda:":[367],"ADOCIA,":[370],"Becton,":[372],"Dickinson":[373],"Zafgen,":[380],"Spouse/Partner;":[383],"Calibra":[392],"Medical,":[393],"Eisai":[394],"Development,":[399],"Theracos,":[404],"N.":[406],"Shehadeh:":[407],"Corp.":[431],"E.":[432,440],"Niemoeller:":[433],"Sanofi.":[436,439,452,523],"Stock/Shareholder;":[437],"Souhami:":[441],"Development.":[447,460,468],"J.":[448,469],"Wu:":[449],"X.":[453],"Wang:":[454],"C.":[461],"Ji:":[462],"Rosenstock:":[470],"Bristol-Myers":[475],"Squibb":[476],"Genentech,":[478],"Melior":[485],"Bukwang":[488],"Pharm.":[489],"Oramed":[496],"PegBio":[498],"Pfizer":[501],"International":[508],"GmbH,":[509],"Funding":[524]},"counts_by_year":[{"year":2021,"cited_by_count":1}],"updated_date":"2026-09-27T08:07:27.782135","created_date":"2019-06-14T00:00:00"}